<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03873610</url>
  </required_header>
  <id_info>
    <org_study_id>2019P000625</org_study_id>
    <nct_id>NCT03873610</nct_id>
  </id_info>
  <brief_title>Resiliency Training in Adolescents With NF1 and NF2</brief_title>
  <official_title>Resiliency Training in Adolescents With NF1 and NF2; A Randomized Controlled Trial Via Secure Live Video Conferencing to Improve Emotional, Social and Physical Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controlled trial for resiliency training in adolescents with&#xD;
      Neurofibromatosis 1 and Neurofibromatosis 2 via secure live video to determine the efficacy&#xD;
      two stress and symptom management programs. Both programs are 8 week group programs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neurofibromatosis (NFs) are rare genetic conditions with cure. Adolescents with NF experience&#xD;
      more symptoms of depression and anxiety, higher levels of stress associated with coping with&#xD;
      NF symptoms, lower levels of self esteem, difficulties with social skills and social support,&#xD;
      high rates of learning disabilities, and more pain as compared with the general population&#xD;
      norms.&#xD;
&#xD;
      The aims of this study are to compare the effect of two stress and symptom management&#xD;
      programs tailored for adolescents with neurofibromatosis on quality of life and psychosocial&#xD;
      functioning. We will also examine the degree to which treatment-dependent improvements in&#xD;
      quality of life are mediated by improvements in depression, pain intensity and pain&#xD;
      interference.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Physical Health Quality of Life</measure>
    <time_frame>0 weeks, 8 weeks, 6 months,12 months</time_frame>
    <description>World Health Organization Quality of Life Brief (WHOQOL-BREF); 4-20; Higher score indicates higher QoL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Psychological Health Quality of Life</measure>
    <time_frame>0 weeks, 8 weeks, 6 months,12 months</time_frame>
    <description>World Health Organization Quality of Life Brief (WHOQOL-BREF); 4-20; Higher score indicates higher QoL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Social relationships Quality of Life</measure>
    <time_frame>0 weeks, 8 weeks, 6 months,12 months</time_frame>
    <description>World Health Organization Quality of Life Brief (WHOQOL-BREF); 4-20; Higher score indicates higher QoL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Environmental Quality of Life</measure>
    <time_frame>0 weeks, 8 weeks, 6 months, 12 months</time_frame>
    <description>World Health Organization Quality of Life Brief (WHOQOL-BREF); 4-20; Higher score indicates higher QoL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>0 weeks, 8 weeks, 6 months, 12 months</time_frame>
    <description>Patient Health Questionnaire (PHQ-9) Adolescent Version; 0-27; Higher score indicates more symptoms of depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>0 weeks, 8 weeks, 6 months, 12 months</time_frame>
    <description>Generalized Anxiety Disorder (GAD-7) Questionnaire; 0-21; Higher score indicates more symptoms of anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>0 weeks, 8 weeks, 6 months, 12 months</time_frame>
    <description>Numerical Rating Scale; 0-10; Higher score indicates more intense pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain interference</measure>
    <time_frame>0 weeks, 8 weeks, 6 months, 12 months</time_frame>
    <description>Pain Interference Index (PII); 0-36; Higher score indicates more pain interference</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Neurofibromatoses</condition>
  <arm_group>
    <arm_group_label>Stress and Symptom Management Program 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stress and Symptom Management 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Stress and Symptom Management Program 1</intervention_name>
    <description>The Stress and Symptom Management Program 1 introduces and reinforces stress and symptom management for adolescents with NF. The program consists of 8 weekly 45 minute sessions, delivered through videoconferencing.</description>
    <arm_group_label>Stress and Symptom Management Program 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Stress and Symptom Management Program 2</intervention_name>
    <description>The Stress and Symptom Management Program 2 introduces and reinforces stress and symptom management for adolescents with NF. The program consists of 8 weekly 45 minute sessions, delivered through videoconferencing.</description>
    <arm_group_label>Stress and Symptom Management 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has a diagnosis of NF1 or NF2 and is between the ages of 12-17&#xD;
&#xD;
          -  Is capable of completing and fully understanding the informed consent process/assent&#xD;
             and the study procedures and assessments in English; has parental approval for&#xD;
             participation&#xD;
&#xD;
          -  English speaking and at least a 3rd grade self-reported and parent reported reading&#xD;
             level&#xD;
&#xD;
          -  Self reported/parent reported difficulties coping with stress and NF symptoms&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has major medical co-morbidity not NF related expected to worsen in the next 12 months&#xD;
&#xD;
          -  Recent (within past 3 months) change in antidepressant medication&#xD;
&#xD;
          -  Recent participation in cognitive behavioral therapy or relaxation therapy (within&#xD;
             past 3 months)&#xD;
&#xD;
          -  Has significant mental health diagnosis requiring immediate treatment (e.g., untreated&#xD;
             bipolar disorder, psychotic disorder, active substance dependence)&#xD;
&#xD;
          -  Unable or unwilling to complete assessments electronically via REDCap&#xD;
&#xD;
          -  Unable or unwilling to participate in group videoconferencing sessions&#xD;
&#xD;
          -  Unable or unwilling to participate along with at least 1 parent in a video screening&#xD;
             session&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana-Maria Vranceanu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ana-Maria Vranceanu, PhD</last_name>
    <phone>6176437996</phone>
    <email>avranceanu@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mira R Reichman, BA</last_name>
    <phone>617-643-4127</phone>
    <email>mreichman@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ana-Maria Vranceanu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2019</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Ana-Maria Vranceanu, PhD</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Neurofibromatosis 1</mesh_term>
    <mesh_term>Neurofibroma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

